Ibio Inc
Change company Symbol lookup
Select an option...
IBIO Ibio Inc
ADAG Adagene Inc
TSLA Tesla Inc
APCX AppTech Payments Corp
CURV Torrid Holdings Inc
MMSBF Megmilk Snow Brand Co Ltd
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
CEFC Commercial National Financial Corp (Michigan)
CNVCF Bioharvest Sciences Inc
GECC Great Elm Capital Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

Closing Price
$0.77
Day's Change
0.0194 (2.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.8075
Day's Low
0.7222
Volume
(Heavy Day)
Volume:
304,096

10-day average volume:
222,520
304,096

Company Profile

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
3.81x
Price/Book (MRQ)
0.14x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

January 2023
Current Month
1.6M
Previous Month
1.1M
Percent of Float
14.93%
Days to Cover
1.1503 Days

Share Information

IBIO is in a share class of common stock
Float
8.8M
Shares Outstanding
11.0M
Institutions Holding Shares
48
12.94%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • William D. Clark
  • Martin B. BrennerCEO
  • Robert Matthew LutzCo-CEO
  • Gary L. Sender
  • Linda Washington Armstrong

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.